IS6104A - Adjustment of the stimulated tissue by topical erythropoietin application - Google Patents

Adjustment of the stimulated tissue by topical erythropoietin application

Info

Publication number: IS6104A
Authority: IS; Iceland
Prior art keywords: adjustment; application; stimulated tissue; erythropoietin; topical
Prior art date: 1999-04-13

Application number

IS6104A

Other languages

Icelandic (is)

Inventor

Brines Michael

Cerami Anthony

Cerami Carla

Original Assignee

Kenneth S. Warren Institute, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-13

Filing date

2001-10-11

Publication date

2001-10-11

2001-10-11 Application filed by Kenneth S. Warren Institute, Inc. filed Critical Kenneth S. Warren Institute, Inc.

2001-10-11 Publication of IS6104A publication Critical patent/IS6104A/en

Links

102000003951 Erythropoietin Human genes 0.000 title 1
108090000394 Erythropoietin Proteins 0.000 title 1
229940105423 erythropoietin Drugs 0.000 title 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
230000000699 topical effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IS6104A 1999-04-13 2001-10-11 Adjustment of the stimulated tissue by topical erythropoietin application IS6104A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29093899A	1999-04-13	1999-04-13
US54722000A	2000-04-11	2000-04-11
PCT/US2000/010019 WO2000061164A1 (en)	1999-04-13	2000-04-13	Modulation of excitable tissue function by peripherally administered erythropoietin

Publications (1)

Publication Number	Publication Date
IS6104A true IS6104A (en)	2001-10-11

Family

ID=26966493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6104A IS6104A (en)	1999-04-13	2001-10-11	Adjustment of the stimulated tissue by topical erythropoietin application

Country Status (21)

Country	Link
EP (1)	EP1171147A4 (en)
JP (1)	JP2003520194A (en)
KR (2)	KR101012932B1 (en)
CN (1)	CN1607957B (en)
AU (1)	AU784550B2 (en)
BG (1)	BG65353B1 (en)
BR (1)	BR0009737A (en)
CA (1)	CA2383940A1 (en)
CR (1)	CR6501A (en)
CZ (1)	CZ20013695A3 (en)
EA (1)	EA004766B1 (en)
HU (1)	HUP0201598A3 (en)
IL (2)	IL145895A0 (en)
IS (1)	IS6104A (en)
MX (1)	MXPA01010177A (en)
NO (1)	NO20014991L (en)
NZ (4)	NZ533098A (en)
PL (1)	PL352223A1 (en)
SK (1)	SK14412001A3 (en)
TR (2)	TR200103785T2 (en)
WO (1)	WO2000061164A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19857609A1 (en)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Use of erythropoietin for the treatment of human cerebral ischemia
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
EP1295604B1 (en)	2000-06-30	2009-09-30	Tokyo Metropolitan Institute of Gerontology	Preventives and remedies for diseases in association with demyelination
DE10043457A1 (en) *	2000-09-04	2002-03-28	Hannelore Ehrenreich	Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en) *	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
NZ548578A (en) *	2001-02-02	2008-03-28	Ortho Mcneil Pharm Inc	Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) *	2001-12-07	2003-06-26	Anthony Cerami	Immune modulation device for use in animals
CN100347306C (en)	2001-10-29	2007-11-07	克鲁塞尔荷兰公司	Methods and means for producing proteins with predetermined post-translational modifications
JP4480398B2 (en)	2001-12-07	2010-06-16	クルセルホランドベーヴェー	Method for producing virus, virus isolate and vaccine
CA2476538C (en)	2002-01-09	2012-07-17	Crucell Holland B.V.	Use of erythropoietin for the preventive or curative treatment of cardiac failure
AU2002307635A1 (en) *	2002-04-19	2003-11-03	Crucell Holland B.V.	Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en)	2002-05-21	2002-06-26	Univ Belfast	Medicaments
US20040122216A1 (en) *	2002-07-01	2004-06-24	Jacob Nielsen	Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (en) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Use of erythropoietin
US7396913B2 (en)	2002-10-14	2008-07-08	Abbott Laboratories	Erythropoietin receptor binding antibodies
WO2004087063A2 (en) *	2003-03-27	2004-10-14	Janssen Pharmaceutica Nv	Use of erythropoietin in stroke recovery
US7718363B2 (en)	2003-04-25	2010-05-18	The Kenneth S. Warren Institute, Inc.	Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
KR101183770B1 (en)	2003-05-09	2012-09-17	크루셀 홀란드 비.브이.	Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004063927A1 (en) *	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en)	2004-11-09	2007-03-15	Medizinische Uni Wien Muw	PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
HUE035655T2 (en)	2005-08-05	2018-05-28	Araim Pharmaceuticals Inc	Tissue protective peptides and uses thereof
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
GB0525540D0 (en) *	2005-12-15	2006-01-25	Isis Innovation	New treatment
DE102006004008A1 (en)	2006-01-27	2007-08-02	Hannelore Prof. Dr. Dr. Ehrenreich	Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) *	2006-04-29	2007-10-31	中国科学院上海生命科学研究院	Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) *	2006-07-20	2012-03-13	Rosalind Franklin University Of Medicine And Science	Facilitation of resuscitation from cardiac arrest by erythropoietin
CN101610782A (en) *	2007-01-10	2009-12-23	爱迪生药物公司	Treatment of respiratory chain disorders with compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) *	2007-07-19	2009-01-22	Hannelore Ehrenreich	Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
NZ621196A (en)	2008-01-22	2015-08-28	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2385746C1 (en) *	2008-07-18	2010-04-10	Владимир Алексеевич Шатров	Method of treating infantile cerebral paralysis
RU2432899C1 (en) *	2010-03-23	2011-11-10	Владимир Алексеевич Тупиков	Method of predicting recurrence of equinus and equinovarus foot deformations after their early surgery in children with cerebral palsy
RU2519695C2 (en) *	2010-07-21	2014-06-20	Олег Ильич Эпштейн	Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) *	2019-12-20	2021-08-27	中国人民解放军陆军军医大学	Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6197229A (en) *	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	Stable erythropoietin preparation
US5614184A (en) *	1992-07-28	1997-03-25	New England Deaconess Hospital	Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
DE19857609A1 (en) *	1998-12-14	2000-06-15	Hannelore Ehrenreich	Use of erythropoietin for the treatment of human cerebral ischemia

2000
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 CN CN008087466A patent/CN1607957B/en not_active Expired - Lifetime
- 2000-04-13 EA EA200101073A patent/EA004766B1/en not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en not_active Ceased
- 2000-04-13 IL IL14589500A patent/IL145895A0/en unknown
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/en unknown
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/en not_active Expired - Fee Related
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/en not_active Application Discontinuation
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/en not_active Application Discontinuation
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/en not_active Expired - Fee Related
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/en active IP Right Grant
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 PL PL00352223A patent/PL352223A1/en not_active Application Discontinuation
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/en unknown
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/en active Pending
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/en unknown
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/en unknown
- 2000-04-13 NZ NZ560696A patent/NZ560696A/en not_active IP Right Cessation
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
2001
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-11 IS IS6104A patent/IS6104A/en unknown
- 2001-10-12 NO NO20014991A patent/NO20014991L/en not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/en unknown
- 2001-11-13 CR CR6501A patent/CR6501A/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ20013695A3 (en)	2002-02-13
EP1171147A1 (en)	2002-01-16
HUP0201598A3 (en)	2002-10-28
KR101012932B1 (en)	2011-02-08
CN1607957A (en)	2005-04-20
TR200402194T2 (en)	2004-10-21
WO2000061164A1 (en)	2000-10-19
NZ560696A (en)	2010-03-26
IL145895A0 (en)	2002-07-25
AU784550B2 (en)	2006-05-04
TR200103785T2 (en)	2002-06-21
EA200101073A1 (en)	2002-10-31
KR20020000874A (en)	2002-01-05
CR6501A (en)	2004-04-15
IL145895A (en)	2010-05-31
AU4348700A (en)	2000-11-14
EP1171147A4 (en)	2003-05-14
NZ545478A (en)	2008-04-30
BR0009737A (en)	2003-01-14
KR100883232B1 (en)	2009-02-10
PL352223A1 (en)	2003-08-11
NZ514690A (en)	2004-07-30
MXPA01010177A (en)	2004-09-10
NO20014991L (en)	2001-11-15
NO20014991D0 (en)	2001-10-12
JP2003520194A (en)	2003-07-02
NZ533098A (en)	2006-04-28
CA2383940A1 (en)	2000-10-19
HUP0201598A2 (en)	2002-09-28
BG65353B1 (en)	2008-03-31
CN1607957B (en)	2012-10-10
KR20070094997A (en)	2007-09-27
EA004766B1 (en)	2004-08-26
SK14412001A3 (en)	2002-03-05
BG106058A (en)	2002-12-29

Publication	Publication Date	Title
DE60013863D1 (en)	2004-10-21	PHOTOCHROMIC INDENO-CONDENSED NAPHTOPYRANE
EE200100628A (en)	2003-02-17	Wind farm
DE60030303D1 (en)	2006-10-05	CANNABIMIMETIC INDOOR DERIVATIVES
DE69934805D1 (en)	2007-02-22	SUBSTITUTED IMIDAZOLE WITH CYTOKIN-INHIBITED EFFECT
DE60026748D1 (en)	2006-05-11	thermostat
EE200200673A (en)	2004-06-15	Quinazoline derivatives for the treatment of tumors
IS2277B (en)	2007-09-15	Therapeutic baryl derivatives
DE69916329D1 (en)	2004-05-13	COSMETIC FORMULATION
ATE333264T1 (en)	2006-08-15	AQUEOUS COSMETIC COMPOSITION WITH IMPROVED STABILITY
DE60017328D1 (en)	2005-02-17	Altimeter with coupled double slide
DE59906732D1 (en)	2003-10-02	adjustment
DE50013404D1 (en)	2006-10-12	SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES
DE60009154D1 (en)	2004-04-22	Phenylpiperazinyl DERIVATIVES
DE50005284D1 (en)	2004-03-18	SUBSTITUTED N-BENZYL-INDOL-3-YL-GLYOXYLIC ACID DERIVATIVES WITH ANTITUARY EFFECT
DE60004583D1 (en)	2003-09-25	regulator
NO20003965D0 (en)	2000-08-04	New dihydroxyhexanoic acid derivatives
IT1319847B1 (en)	2003-11-03	POWER SUPPLY.
DE122011100028I1 (en)	2011-12-08	Novel imidazole with anti-inflammatory effect.
DE60039349D1 (en)	2008-08-14	ELECTROCHEMICAL CONDENSER
IT1316059B1 (en)	2003-03-28	SKIN DEPIGMENTANTS.
TR200002831A3 (en)	2001-04-20	Quinolin-4-Il derivatives I
DE50003777D1 (en)	2003-10-30	voltage regulators
NO992518L (en)	2000-11-27	element Organ
DE50007499D1 (en)	2004-09-23	COSMETIC EMULSIONS
NO993137L (en)	2000-12-27	underreamed